Search results

  1. MSK 16-1536 (LYT209447)

    … and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma Cancer …

  2. OZM-109 (LYTOZM109)

    … R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma Cancer …

  3. HDC.1 (LYHDC1)

    … with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Drug Name …

  4. Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.

    … Journal Clin Lymphoma Myeloma Leuk, 2025 …

  5. DS3201-A-U202 (LYTAU202)

    … in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma  Cancer …

  6. Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based..

    … Journal Leuk Lymphoma, 2024 …

  7. LY.17 (LYLY17)

    … the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma Cancer …

  8. Clinical Trials

    … tongue Hematology (blood cancer) includes leukemia, lymphoma and multiple myeloma     BC Cancer …

  9. Lymphoid Cancer Research

    … patient outcomes by gaining a deeper understanding of lymphoma biology and progression, for use in clinical …

  10. Recipients of Round Two of the 2024 BC Cancer Clinician Researcher Start Up Competition Announced

    … of the Intestinal Microbiome in Patients with Mantle Cell Lymphoma Juanita Crook (BC Cancer – Kelowna): …

    Dec 3, 2024

Back to top